Trevi Therapeutics Cash Flow Statement
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.19+0.365 (+2.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Trevi Therapeutics free cash flow
In fiscal 2025, Trevi Therapeutics generated -$42.1 million of operating cash flow and spent $12,000 on capital expenditures. That left free cash flow of -$42.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Trevi Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M | -32.76M | -26.05M | -20.55M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 144.00K | 147.00K | 123.00K | 43.00K | 50.00K | 47.00K | 39.00K | 23.00K |
| Stock-Based Compensation | 5.18M | 3.59M | 2.25M | 2.33M | 2.54M | 2.42M | 1.13M | 496.00K |
| Change in Working Capital | -3.49M | 6.83M | -3.85M | -1.23M | 1.51M | 1.06M | 1.82M | 703.00K |
| Operating Cash Flow | -42.09M | -38.26M | -31.71M | -28.18M | -28.95M | -29.00M | -23.09M | -18.29M |
| Capital Expenditures | -12.00K | -35.00K | -137.00K | -159.00K | — | -32.00K | -9.00K | -158.00K |
| Investing Cash Flow | -94.11M | -21.53M | 59.43M | -107.37M | — | -32.00K | -9.00K | -158.00K |
| Debt Issued | — | — | — | — | — | 14.00M | — | — |
| Debt Repaid | — | — | — | -5.83M | — | — | — | -4.81M |
| Financing Cash Flow | 121.01M | 61.48M | -7.91M | 111.31M | 20.77M | 16.72M | 73.21M | 3.63M |
| Net Change in Cash | -15.18M | 1.70M | 19.81M | -24.24M | -8.17M | -12.31M | 50.11M | -14.82M |
| Free Cash Flow | -42.10M | -38.29M | -31.85M | -28.33M | -28.95M | -29.03M | -23.10M | -18.45M |
This table shows 8 annual periods of Trevi Therapeutics's cash flow statement, from FY 2025 back to FY 2018, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TRVI's reporting calendar. What is a cash flow statement?